Meldungen zum Thema Enterprises

Folgen
Keine Meldung zum Thema Enterprises mehr verpassen.
Filtern
  • 26.03.2010 – 00:02

    Elliott Advisors

    Elliott Issues Truvo Subsidiary Corp. Statement

    New York, March 25, 2010 (ots/PRNewswire) - Elliott Associates, L.P. (together with funds under common management), today issued the following statement regarding Truvo Subsidiary Corp. "Elliott welcomes the announcement by Truvo that it has obtained consent under the Senior Facilities Agreement to commence debt restructuring negotiations with holders of the Notes." Elliott holds 32% of the Notes and also holds ...

  • 24.03.2010 – 18:42

    Agendia B.V.

    Agendia Launches BluePrint(TM) Expanding Breast Cancer Product Offering

    HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor ...

  • 19.03.2010 – 15:20

    Mundipharma International

    Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers

    Cambridge, England, March 19, 2010 (ots/PRNewswire) - Mundipharma announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending that marketing authorisations can be granted in Germany and the following Member States of the EU: Austria, Belgium, Denmark, Finland, ...

  • 19.03.2010 – 12:09

    Roche Pharmaceuticals

    Tarceva Receives Positive Opinion in Europe for Maintenance Treatment of Advanced Lung Cancer

    Basel, Switzerland, March 19, 2010 (ots/PRNewswire) - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely ...

  • 19.03.2010 – 08:52

    Valeo Management Services

    Valeo Announces Project to Sell Speed Controller Activity

    Paris, March 19, 2010 (ots/PRNewswire) - Valeo today announced a project to sell its Telma speed controller activity, which manufactures electromagnetic retarders, to the current management team. The operation includes the activity's headquarters and main plant based in Saint Ouen l'Aumône, France, a joint venture plant in China and two distribution centers based in the U.K. and the U.S. The business employs 195 ...

  • 17.03.2010 – 17:01

    Agendia B.V.

    Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer

    HUNTINGTON BEACH, California and AMSTERDAM, March 17, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites. I-SPY 2 is an exciting and groundbreaking new clinical trial model that will help scientists quickly and efficiently test the most ...

  • 17.03.2010 – 10:32

    Stallergenes

    /C O R R E C T I O N -- Stallergenes/

    Antony, France, March 17, 2010 (ots/PRNewswire) - In the news release, "STALLERGENES 2009 : Further Profit Margin Growth and Significant Cash Generation Further Profit Margin Growth and Significant Cash Generation:" issued on 16 Mar 2010 19:50 GMT, by Stallergenes Bloomberg:GENP@FP over PR Newswire, we are advised by a representative of the company that in the section headed '2010 outlook' the second paragraph, ...

  • 17.03.2010 – 07:40

    Biosign Technologies Inc.

    Biosign Receives Reimbursement Approval from NexgenRx

    Toronto, March 17, 2010 (ots/PRNewswire) - Biosign Technologies Inc. (CNSX: BIO) (the "Company" or "Biosign") today announced it has received notification that NexgenRx will include Biosign's UFIT(R) device and services into their Benefits Plans for reimbursement according to regulatory clearances in the relevant jurisdiction. Ronald C. Louks, President & CEO of NexgenRx, said: "We see diabetic plan members ...

  • 10.03.2010 – 16:07

    PUMA AG Rudolf Dassler Sport

    PUMA Acquires Equipment Brand Cobra Golf

    Herzogenaurach, Germany, March 10, 2010 (ots/PRNewswire) - Sportlifestyle company PUMA announces today that it has signed an agreement to acquire 100 percent of the golf equipment brand Cobra Golf from Acushnet Company, the golf business of Fortune Brands, Inc. The acquisition includes the Cobra brand as well as related inventory, intellectual property and endorsement contracts and is subject to customary closing ...

  • 10.03.2010 – 08:04

    Valeo Management Services

    Valeo Presents New Strategic Plan and Medium-Term Financial Objectives

    Paris, March 10, 2010 (ots/PRNewswire) - During an investor day organized today in Paris, Valeo presented its new strategic plan focused on CO2 emissions reduction and its medium-term financial objectives: - organic growth higher than that of automotive production in each region thanks to innovation and accelerated development in emerging markets; - ...

  • 09.03.2010 – 22:55

    Abbott Laboratories

    Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

    ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 (ots/PRNewswire) -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. Abbott will acquire Facet for US$27 per share in cash for a net transaction value of approximately US$450 ...

  • 09.03.2010 – 01:02

    Pediatric Dengue Vaccine Initiative (PDVI)

    The Pediatric Dengue Vaccine Initiative Introduces www.DengueWatch.org - a News hub for Tracking Dengue Fever Epidemics Worldwide

    Seoul, March 9, 2010 (ots/PRNewswire) - PDVI (Pediatric Dengue Vaccine Initiative), a program of the International Vaccine Institute (IVI) funded by the Bill & Melinda Gates Foundation, announces today the launch of http://www.denguewatch.org, a news hub for tracking dengue fever epidemics worldwide. Breaking ...

  • 08.03.2010 – 16:47

    Bank Nederlandse Gemeenten

    BNG Profit EUR 278 Million

    The Hague, The Netherlands, March 8, 2010 (ots/PRNewswire) - BNG closes the 2009 financial year with a net profit of EUR 278 million (2008: EUR 158 million). As a result of the low money market interest rate, interest results have risen by EUR 60 million. The increased marketability of interest bearing securities has lead to an increase of the result financial transactions by EUR 104 million. The proposed dividend payout to shareholders amounts to EUR 139 million. BNG ...